Prosecution Insights
Last updated: May 29, 2026

Examiner: ROGERS, JAMES WILLIAM

Tech Center 1600 • Art Units: 1618

This examiner grants 46% of resolved cases

Performance Statistics

46.3%
Allow Rate
-13.7% vs TC avg
944
Total Applications
+21.8%
Interview Lift
1409
Avg Prosecution Days
Based on 896 resolved cases, 2023–2026

Rejection Statute Breakdown

0.4%
§101 Eligibility
4.1%
§102 Novelty
73.4%
§103 Obviousness
2.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19218211 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Non-Final OA Veradermics, Incorporated
19288889 CLEANSERS Final Rejection Dr. Squatch, LLC
19249149 STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF Non-Final OA Nivagen Pharmaceuticals, Inc.
19249060 STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF Non-Final OA Nivagen Pharmaceuticals, Inc.
17614638 pH RESPONSIVE COMPOSITIONS AND USES THEREOF Final Rejection The Board of Regents of The University of Texas System
17744080 LOW MOLECULAR WEIGHT AND POLYAMIDOAMINE (PAMAM) DENDRIMER BASED PSMA-SPECIFIC DUAL CONTRAST AGENTS FOR OPTICAL AND PHOTOACOUSTIC IMAGING AND THERANOSTIC AGENTS FOR TREATING PROSTATE CANCER Final Rejection The Johns Hopkins University
17771142 POLYMERIC NANOPARTICLES FOR INTRACELLULAR PROTEIN DELIVERY Final Rejection The Johns Hopkins University
18208672 PROTEIN-TEMPLATED SELF-ASSEMBLY OF A COVALENT POLYMER NETWORK FOR INTRACELLULAR TRAFFICKING AND TRACELESS RELEASE Non-Final OA University of Massachusetts
17997908 POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION AND METHOD FOR DETECTION OF BACTERIAL INFECTION Non-Final OA The Research Foundation for the State University of New York
18282705 ULTRASMALL GADOLINIUM-INTERCALATED CARBON DOTS AS A RADIOSENSITIZING AGENT FOR CANCER Non-Final OA UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
18240138 ORTHOPEDIC ATTACHMENT SYSTEMS AND METHODS THEREOF Non-Final OA Anika Therapeutics, Inc.
17790698 OXAZINE-BASED WATER-SOLUBLE FLUOROPHORE COMPOUNDS FOR IN VIVO NERVE IMAGING Final Rejection Oregon Health & Science University
18119348 BIOSENSING COMPOSITION HAVING SENSING GLUCOSE CONTENT, CONTACT LENS AND METHOD OF PREPARATION THEREOF Non-Final OA National Yang Ming Chiao Tung University
17064352 INORGANIC NANOCAGES, AND METHODS OF MAKING AND USING SAME Final Rejection Cornell University
17898995 MASKED FLUOROGENIC COMPOUNDS AND METHODS OF USING THE SAME Non-Final OA Rutgers, The State University of New Jersey
17781731 CONTRAST AGENT FOR 3D EX VIVO IMAGING OF VASCULAR AND TUBULAR STRUCTURES IN THE KIDNEY Final Rejection UNIVERSITÄT ZÜRICH
18460656 PHARMACEUTICAL COMPOSITION CONTAINING ETHANOL AND USE THEREOF Non-Final OA SUZHOU YIBEN LIFE TECHNOLOGY CO., LTD
18548898 CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF Non-Final OA STARGET PHARMA LTD.
17693262 CROSS-LINKED POLYMER MODIFIED NANOPARTICLES Final Rejection PDX Pharmaceuticals, Inc.
17754532 NON DEGRADABLE RADIO-OPAQUE EMBOLISATION MICROSPHERE Non-Final OA GUERBET
17665316 TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES Final Rejection Lithea AB
18054149 Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis Final Rejection Primo Biotechnology Co., Ltd
17922830 HEMOSTATIC POLYMER MATERIAL KIT Non-Final OA GELLYCLE CO., LTD.
17792336 COMPOSITION COMPRISING A FLUOROPHORE LABELLED UPAR-TARGETING PEPTIDE CONJUGATE Final Rejection FLUOGUIDE A/S
17787545 NOVEL MANUFACTURING PROCESS FOR GADOLINIUM COMPLEXES Non-Final OA GE Healthcare AS
17755671 pH Responsive Block Copolymers Compositions, Micelles, and Methods of Use Non-Final OA ONCONANO MEDICINE, INC
17453129 METHOD FOR BONE HEALING OR TREATMENT OF BONE FRACTURE Final Rejection Moroxite AB
17245504 PARTICLE COMPRISING AT LEAST ONE FERRIMAGNETIC OR FERROMAGNETIC IRON OXIDE NANOPARTICLE ASSOCIATED WITH AT LEAST ONE COMPOUND FOR MEDICAL OR COSMETIC USE Non-Final OA AlphaOnco

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month